0001193125-21-041625.txt : 20210212 0001193125-21-041625.hdr.sgml : 20210212 20210212162558 ACCESSION NUMBER: 0001193125-21-041625 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20210212 DATE AS OF CHANGE: 20210212 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Neoleukin Therapeutics, Inc. CENTRAL INDEX KEY: 0001404644 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-88050 FILM NUMBER: 21627992 BUSINESS ADDRESS: STREET 1: SUITE 360 - 1616 EASTLAKE AVE EAST CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-732-2133 MAIL ADDRESS: STREET 1: SUITE 360 - 1616 EASTLAKE AVE EAST CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: AQUINOX PHARMACEUTICALS, INC DATE OF NAME CHANGE: 20140128 FORMER COMPANY: FORMER CONFORMED NAME: AQUINOX PHARMACEUTICALS (USA) INC DATE OF NAME CHANGE: 20070626 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Silva Manzano Daniel Adriano CENTRAL INDEX KEY: 0001803051 FILING VALUES: FORM TYPE: SC 13G MAIL ADDRESS: STREET 1: 360-1616 EASTLAKE AVENUE E. CITY: SEATTLE STATE: WA ZIP: 98102 SC 13G 1 d78081dsc13g.htm SC 13G SC 13G

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

 

 

Neoleukin Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.000001 per share

(Title of Class of Securities)

64049K104

(CUSIP Number)

December 31, 2020

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

   SCHEDULE 13G   
CUSIP No. 64049K104       Page 2 of 4 Pages

 

  1    

  NAME OF REPORTING PERSON

  S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

 

  Daniel Adriano Silva Manzano

  2  

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

  (a)  ☐        (b)  ☐

 

  3  

  SEC USE ONLY

 

      

  4  

  CITIZENSHIP OR PLACE OF ORGANIZATION

 

  Mexico

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

    5     

  SOLE VOTING POWER

 

  2,938,146

   6   

  SHARED VOTING POWER

 

  0

   7   

  SOLE DISPOSITIVE POWER

 

  2,938,146

   8   

  SHARED DISPOSITIVE POWER

 

  0

  9    

  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

  2,938,146

10  

  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)  ☐

 

  

11  

  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

  6.96%

12  

  TYPE OF REPORTING PERSON (See Instructions)

 

  IN

 

   SCHEDULE 13G   
CUSIP No. 64049K104       Page 3 of 4 Pages

 

Item 1.

 

  (a)

Name of Issuer:

Neoleukin Therapeutics, Inc.

 

  (b)

Address of Issuer’s Principal Executive Offices:

1616 Eastlake Avenue East, #360

Seattle, Washington 98102

 

Item 2.

 

  (a)

Name of Person Filing:

Daniel Adriano Silva Manzano

 

  (b)

Address of Principal Office:

c/o Neoleukin Therapeutics, Inc.

1616 Eastlake Avenue East, #360

Seattle, Washington 98102

 

  (c)

Citizenship:

Mexico

 

  (d)

Title of Class of Securities:

Common Stock

 

  (e)

CUSIP Number:

64049K104

 

Item 3.

Statement Filed Pursuant to Rule 13d-1(b) or 13d-2(b) or (c):

Not applicable.

 

Item 4.

Ownership.

 

  (a)

Amount beneficially owned:

2,938,146

 

  (b)

Percent of class:

6.96%

(c) Number of shares as to which the person has:

 

(i)

    Sole power to vote or to direct the vote:      2,938,146  

(ii)

    Shared power to vote or to direct the vote:      0  

(iii)

    Sole power to dispose or to direct the disposition of:      2,938,146  

(iv)

    Shared power to dispose or to direct the disposition of:      0  

 

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☐.

 

Item 6.

Ownership of More Than Five Percent on Behalf of Another Person.

Not Applicable.

 

Item 7.

Identification and Classification of Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

Not applicable.

 

Item 8.

Identification and Classification of Members of the Group

Not applicable.

 

Item 9.

Notice of Dissolution of Group

Not applicable.

 

Item 10.

Certifications

Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: February 12, 2021     By:  

/s/ Daniel Adriano Silva Manzano

    Name:   Daniel Adriano Silva Manzano